Lymphoma

>

Latest News

light blue background with a white outline indicating blood cells
Positive Responses to Liso-Cel Observed in Relapsed/Refractory Marginal Zone Lymphoma

February 16th 2025

Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

Image that reads "FDA APPROVED," where the word "approved" looks like a stamp of approval, on a green background
FDA Approves Brentuximab Vedotin Combo for Relapsed/Refractory Large B-Cell Lymphoma

February 12th 2025

Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard
Oncology Drugs Approved by the FDA in January 2025

February 3rd 2025

Simple white line illustration of red blood cells on a yellow background
Evaluating the Risk of Second Primary Cancers After CAR T-Cell Therapy

January 30th 2025

green background with blue text indicating FDA and dark green text indicating approval with a check mark
FDA Approves Acalabrutinib-Based Regimen for Previously Treated MCL

January 16th 2025

More News